Company Filing History:
Years Active: 2019-2022
Title: The Innovative Contributions of Per Ekström
Introduction
Per Ekström is a notable inventor based in Lund, Sweden, recognized for his significant contributions to the field of pharmaceuticals and drug delivery systems. With a total of two patents to his name, Ekström has focused on developing innovative solutions that address critical medical challenges.
Latest Patents
Ekström's latest patents include "Equatorially modified polymer linked multimers of guanosine-3', 5'-cyclic monophosphates" and "Targeted liposomal delivery of cGMP analogues." The first patent involves new equatorially modified polymer linked multimers of guanosine-3', 5'-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system. This invention also encompasses related monomeric compounds that may serve as precursors for the multimers and exhibit inhibitory activity. The compounds are intended for use in signal transduction research and as modulators of cyclic nucleotide-regulated binding proteins. The second patent focuses on targeted drug delivery methods for therapeutic agents across the blood-ocular barrier, specifically using cyclic guanosine-3', 5'-monophosphate analogs to treat retinal diseases.
Career Highlights
Throughout his career, Per Ekström has worked with several prominent companies, including Mireca Medicines GmbH and Graybug Vision, Inc. His work has significantly advanced the understanding and treatment of various medical conditions, particularly in the realm of retinal health.
Collaborations
Ekström has collaborated with notable professionals in his field, including Valeria Marigo and Hans-Gottfried Genieser. These partnerships have contributed to the development of innovative solutions and have enhanced the impact of his work.
Conclusion
Per Ekström's contributions to the field of pharmaceuticals and drug delivery systems exemplify the importance of innovation in addressing medical challenges. His patents reflect a commitment to advancing healthcare through scientific research and collaboration.